...
首页> 外文期刊>American Journal of Surgical Pathology >Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas
【24h】

Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas

机译:具有BCL6和MYC易位的双击B细胞淋巴瘤是侵袭性的,常为结外淋巴瘤,与BCL2双击B细胞淋巴瘤不同

获取原文
获取原文并翻译 | 示例
           

摘要

Double-hit (DH) lymphomas with MYC and either BCL2 (DH-BCL2/MYC) or BCL6 (DH-BCL6/MYC) rearrangements are considered very aggressive, many of which are now included in the category B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) (DLBCL/BL). However, data describing the DH cases are largely based on DH-BCL2/MYC cases. To better characterize DH-BCL6/MYC cases, the clinical, morphologic, phenotypic, and cytogenetic features of 6 cases from University of Pittsburgh Medical Center and 17 cases from the Mitelman database were reviewed. In the University of Pittsburgh Medical Center cases, the median age was 83 years (range, 51 to 89 y) with 5/6 DLBCL/BL cases and 1 large B-cell lymphoma, not otherwise specified. Five of 6 had a germinal center phenotype, 1/6 was BCL2, and the median Ki-67 score was 98% (35% to 100%). The Mitelman DH-BCL6/MYC cases included 13 aggressive B-cell lymphomas (diagnosed as DLBCL-5, BL-5, BL-like lymphomas-2, and primary effusion lymphoma-1) and 4 other lymphoid/plasmacytic neoplasms. The median cytogenetic complexity score was 2.5 (range, 0 to 14) in 14 evaluable mature aggressive lymphomas with an immunoglobulin gene partner for MYC in 9/14 and for BCL6 in 7/14 cases. Ten of 13 cases involved extranodal extramedullary sites at presentation, and the median survival for the 10 patients with large cell neoplasms or BL and with available follow-up data was 9 months. Thus, DH-BCL6/MYC lymphomas are aggressive, frequently involve extranodal sites, and are often DLBCL/BL with a germinal center phenotype. Unlike DH-BCL2/MYC lymphomas, however, they are more likely to be CD10 but IRF4/MUM-1 (P=0.03) and, more like BL, only infrequently express BCL2 (P<0.001), and are cytogenetically less complex (P<0.04).
机译:患有MYC和BCL2(DH-BCL2 / MYC)或BCL6(DH-BCL6 / MYC)重排的双发(DH)淋巴瘤被认为具有很强的侵袭性,其中许多现已归类为B细胞淋巴瘤,无法分类,具有介于弥漫性大B细胞淋巴瘤(DLBCL)和伯基特淋巴瘤(BL)(DLBCL / BL)之间的特征。但是,描述DH病例的数据主要基于DH-BCL2 / MYC病例。为了更好地表征DH-BCL6 / MYC病例,对匹兹堡大学医学中心的6例和Mitelman数据库的17例的临床,形态,表型和细胞遗传学特征进行了回顾。在匹兹堡大学医学中心的病例中,年龄中位数为83岁(范围为51至89岁),其中5/6 DLBCL / BL例和1例大B细胞淋巴瘤(未另作说明)。 6个中的5个具有生发中心表型,BCL2为1/6,中位数Ki-67得分为98%(35%至100%)。 Mitelman DH-BCL6 / MYC病例包括13例侵袭性B细胞淋巴瘤(诊断为DLBCL-5,BL-5,BL样淋巴瘤2和原发渗出性淋巴瘤1)和其他4个淋巴样/浆液性肿瘤。在14个可评估的成熟侵袭性淋巴瘤中,具有9/14的MYC和7/14的BCL6的免疫球蛋白基因伴侣的中位细胞遗传学复杂性评分为2.5(范围为0至14)。 13例中有10例在报告时涉及结外髓外部位,而10例具有大细胞肿瘤或BL并有随访资料的患者的中位生存期为9个月。因此,DH-BCL6 / MYC淋巴瘤是侵袭性的,经常涉及结外部位,并且通常是具有生发中心表型的DLBCL / BL。但是,与DH-BCL2 / MYC淋巴瘤不同,它们更可能是CD10,但是IRF4 / MUM-1(P = 0.03),更像BL,仅很少表达BCL2(P <0.001),并且在细胞遗传学上不那么复杂( P <0.04)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号